XSpray Pharma AB, a prominent player in the health care biotechnology sector, is headquartered in Solna, Sweden. The company is listed on the Swedish Stock Exchange and operates primarily in the biotechnology industry, focusing on particle manufacturing and solid-state characterization services. XSpray Pharma AB is renowned for its expertise in producing formulations of protein kinase inhibitors, which are crucial in modulating biological processes by either accelerating or decelerating them.
As of September 16, 2025, the company’s close price stood at 52.5 SEK. Over the past year, XSpray Pharma AB has experienced significant fluctuations in its stock price, reaching a 52-week high of 65.6 SEK on October 20, 2024, and a low of 23 SEK on April 6, 2025. These variations reflect the dynamic nature of the biotechnology sector and the company’s strategic positioning within it.
With a market capitalization of 1,949,770,620 SEK, XSpray Pharma AB holds a substantial presence in the market. The company’s focus on particle manufacturing and solid-state characterization underscores its commitment to advancing pharmaceutical technologies. By specializing in protein kinase inhibitors, XSpray Pharma AB plays a critical role in the development of therapeutic solutions that target various biological pathways, offering potential advancements in the treatment of numerous diseases.
The company’s strategic initiatives and technological expertise position it as a key player in the biotechnology landscape, contributing to its robust market valuation and ongoing influence in the health care sector.